Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.

Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
Arthritis & Rheumatology (Impact Factor: 7.87). 06/2006; 54(5):1463-72. DOI: 10.1002/art.21767
Source: PubMed

ABSTRACT Intraarticular corticosteroids are frequently used as successful adjuvant therapy for inflammatory arthritides, but little is known about their effects on molecules that regulate bone biology. We undertook this study to investigate the effect of intraarticular corticosteroids on the synovial expression of RANKL and osteoprotegerin (OPG).
We evaluated RANKL, OPG, and surface marker expression by immunohistochemical methods in synovial knee biopsy samples obtained from 13 patients with inflammatory arthritis before and 2 weeks following intraarticular injection of triamcinolone hexacetonide. We further investigated the effect of dexamethasone (DEX) on RANKL expression by lymphocytes from rheumatoid arthritis synovial fluids (RA SF), using flow cytometric analysis. Finally, we evaluated the in vitro effect of DEX on RANKL and OPG expression in osteoblast-like cells, by Western blotting.
Intraarticular corticosteroids induced a decrease in the number of synovial T cells without influencing the number of macrophages, evaluated as both CD68+ and CD163+ cells. This change was paralleled by a decrease of synovial RANKL expression with a concomitant reduction of the RANKL:OPG ratio. DEX down-regulated RANKL expression on lymphocytes derived from RA SF. Moreover, in vitro pretreatment of osteoblast-like cells with tumor necrosis factor favored an antiresorptive effect of DEX treatment through a similar down-regulation of RANKL expression.
The decrease in inflammation attributed to intraarticular corticosteroids is accompanied by down-modulation of bone destruction markers. These findings offer a rationale for the beneficial effect of corticosteroids on joint erosion in arthritis.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim Rheumatoid arthritis is a systemic inflammatory disease, which mainly affects joints but can also affect other organs. Ocimum gratissimum L. (Lamiaceae) is a herb, which is reported to have anti-inflammatory activity. So the present investigation was designed to evaluate antiarthritic potential of O. gratissimum in Collagen induced arthritis (CIA) in laboratory animals. Materials and methods Fresh leaves were extracted using 95% ethanol by maceration process. The extracts were tested against collagen induced female Sprague-Dawley rats. Arthritis assessment was carried out on the basis of parameters including arthritic score, body weight and paw volume. On day 41, animals were evaluated for biochemical parameter, radiological parameter and histological parameters. Results Treatment with 500 mg/kg of EEOG significantly reduced arthritic score, paw volume and almost restored body weight of arthritic animals compared to control animals. Meanwhile, the treatment significantly attenuated biochemical, radiological and histopathological alteration induced by CIA. Conclusion EEOG can able to nullify most of the ill effects produced by CIA in rats. However, further studies are needed to carry out identification, isolation of active fractions of EEOG to unravel the mechanism of drug.
    Biomedicine & Aging Pathology. 07/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased bone resorption and enhanced risk of osteoporotic fractures are often reported in patients with diseases having immune system involvement, mainly inflammatory rheumatic diseases, for which glucocorticoids are more often prescribed because of their powerful antinflammatory effects. Among secondary osteoporosis, glucocorticoid-induced osteoporosis is the most common and severe form, and up to now prolonged glucocorticoid therapy has been considered the most important osteoporotic risk factor in rheumatic patients.However, it is now clear that the pathogenesis of osteoporosis in inflammatory rheumatic diseases is mediated by several factors. In particular, new discoveries within osteoimmunology concerning the complex relationship between bone and immunity, suggest that inflammation itself, through proinflammatory and osteoclastogenic cytokine overexpression, promotes bone resorption leading to increased skeletal fragility. Therefore, by controlling systemic inflammation, it is also possible to reduce the loss of bone mass which accompanies rheumatic diseases.From this point of view, we critically revisit the effects of glucocorticoids on bone in rheumatic diseases, in which they should be seen not just as an enemy of the bone health but eventually as a potential therapeutic tool capable of reducing the risk of osteoporosis by controlling disease activity and inflammation.
    Current Medicinal Chemistry 11/2014; · 3.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The inflammatory joint diseases of juvenile inflammatory arthritis (JIA), rheumatoid arthritis (RA) and osteoarthritis (OA): and also mild to moderate joint injury, all require a multidisciplinary approach to management. Intra-articular injections of corticosteroids have been shown to be a very beneficial adjunctive treatment in the management of the above disorders. It is, therefore, important that clinicians have a good understanding of the clinical actions of intra-articular injections. This article explores the pharmacokinetics, pharmacodynamics, and clinical pharmacology of triamcinolone acetonide (TA) and triamcinolone hexacetonide (TH) in JIA, RA, and OA. Literature search of TA and TH articles was conducted using key word searches in the PubMed and Google Scholar databases and through references within found articles. TA and TH intra-articular injections have been shown to provide good clinical benefit for up to 6 months and even longer. TH has been shown to decrease in the expression of citrullinated proteins, the monoclonal antibody F95, and peptidylarginine deiminase 4 in RA synovium. TA and TH intra-articular injections have a low side effect profile which is similar to other corticosteroid. They have minimal to no mineralocorticoid adverse effects and facial flushing 2-3 days post injections is the most common side effect recorded, and in almost all cases is no worse than nuisance. TA and TH are useful adjunct therapies in the management of JIA, RA, OA, and mild to moderate joint injury.
    Inflammopharmacology 05/2014; 22(4).

Full-text (2 Sources)

Available from
Nov 7, 2014